Conference Coverage

Deciphering lung cancer biomarkers shrouded in tobacco smoke


 

AT AN AACR/IASLC JOINT CONFERENCE

References

In addition, the exposure biomarkers are not entirely predictive and thus, will need to be combined with multiple DNA adducts and repair if susceptible smokers are to be identified and targeted for state-of-the art cessation approaches and surveillance, he said.

Using high-level mass spectrometry, the researchers have been able to readily measure formaldehyde DNA adducts and tobacco-specific 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB)–releasing DNA adducts in human oral cells. Levels of the HPB adduct were unusually high at 12-45 pmol/mg, which is similar to what is seen in animals when exposed to NNK at a much higher dose than smokers take in.

“So this is a real lead,” said Dr. Hecht, who reported having no relevant conflicts of interest.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Alectinib shows promise in crizotinib-refractory ALK-rearranged NSCLC
MDedge Hematology and Oncology
Necitumumab approved as first-line treatment of metastatic squamous NSCLC
MDedge Hematology and Oncology
Alectinib FDA approved to treat metastatic ALK-positive NSCLC*
MDedge Hematology and Oncology
Oncology 2015: new therapies and new transitions toward value-based cancer care
MDedge Hematology and Oncology
Cancer clinical trial enrollment of diverse and underserved patients within an urban safety net hospital
MDedge Hematology and Oncology
Mutation in ALK-rearranged lung cancer confers resistance to lorlatinib, restores sensitivity to crizotinib
MDedge Hematology and Oncology
Former smokers turning to e-cigarettes
MDedge Hematology and Oncology
Late risks of breast cancer RT are higher for smokers
MDedge Hematology and Oncology
Families perceive few benefits from aggressive end-of-life care
MDedge Hematology and Oncology
Adjuvant therapy extends survival in early SCLC
MDedge Hematology and Oncology